United Laboratories International Holdings (SEHK:3933) reported half-year 2026 earnings, with sales of CNY 6,165.95 million and net income of CNY 347.64 million, both lower than the prior-year period.
At a share price of HK$8.41, United Laboratories International Holdings has seen its share price return weaken over shorter periods, including a 30 day share price return down 7.63% and a year to date decline of 28.30%. However, the 5 year total shareholder return of 94.40% still reflects a much stronger long haul outcome, suggesting recent momentum has faded as investors reassess the stock after the weaker half year earnings.
Spot fresh ideas alongside United Laboratories International Holdings by scanning a hand picked 267 high quality undervalued stocks featuring companies with solid cash flows and stronger balance sheets.United Laboratories International Holdings now trades at a sizeable discount to both analyst targets and an estimated fair value, even after the recent sell off on weaker half year results. Is the market being prudently cautious or overly pessimistic about the stock’s outlook and risks?
Preferred P/E of 26.4x: Is it justified for United Laboratories International Holdings?
At the last close of HK$8.41, United Laboratories International Holdings trades on a P/E of 26.4x, which screens as mixed value. It looks inexpensive relative to selected peers but richer than both the broader Hong Kong pharmaceuticals sector and an estimated fair P/E level.
The P/E ratio compares the company’s share price with its earnings per share. For a business like United Laboratories International Holdings, which operates across bulk medicine, intermediates, finished pharmaceuticals, and health products, P/E is a common shorthand for how much investors are willing to pay for each unit of current earnings.
On one side, the stock is described as good value based on its P/E of 26.4x against a peer average of 34.3x. That suggests the market is paying less for each unit of earnings than for similar companies, despite forecasts that earnings could grow 30.71% per year and faster than the wider Hong Kong market expectation of 11.4% per year. On the other side, the same 26.4x P/E is flagged as expensive when stacked against an estimated fair P/E of 22.7x. This is a level the market could reasonably move toward if sentiment normalises.
There is a further contrast against the domestic pharmaceuticals industry, where the average P/E is 14.3x. United Laboratories International Holdings trades at a clear premium to that industry average, which points to investors already baking in stronger earnings growth or higher quality characteristics than the sector as a whole.
Explore the SWS fair ratio for United Laboratories International Holdings.
Result: Price-to-earnings of 26.4x (OVERVALUED)
However, investors in United Laboratories International Holdings still face risk if half year earnings softness persists or if its premium P/E compresses toward sector levels.
Find out about the key risks to this United Laboratories International Holdings narrative.
Another View on United Laboratories International Holdings: DCF Versus P/E
The P/E of 26.4x presents United Laboratories International Holdings as somewhat expensive, yet the SWS DCF model suggests the stock trades about 73% below an estimated fair value of HK$31.53. That is a very wide gap. Is the market correctly sceptical or creating a potential mispricing?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out United Laboratories International Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 267 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment on United Laboratories International Holdings mixed, it helps to move quickly and review the numbers yourself. To see both sides of the story in one place, take a close look at the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond United Laboratories International Holdings?
If you stop at United Laboratories International Holdings, you risk missing other companies that might fit your style better. Put a few more ideas on your radar first.
- Spot potential value plays early by scanning a curated set of underfollowed companies through the 617 high quality undiscovered gems.
- Focus on capital preservation first and filter for companies with steadier profiles using the 282 resilient stocks with low risk scores.
- Prioritise financial strength and filter for companies with robust fundamentals by running the list of solid balance sheet and fundamentals (436 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com